MAP2K7 and triple-negative breast carcinoma: Moreover, Zawistowski et al. found that the MEK inhibitor trametinib induces enhancer remodeling during adaptive resistance and that JQ1 can overcome this resistance by impairing enhancer remodeling in triple-negative breast cancer (TNBC) [42].